IRIS
PRETE, MARCELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.903
EU - Europa 3.658
AS - Asia 3.391
SA - Sud America 876
Continente sconosciuto - Info sul continente non disponibili 458
AF - Africa 162
OC - Oceania 6
Totale 16.454
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.635
IT - Italia 1.658
SG - Singapore 1.351
CN - Cina 727
BR - Brasile 674
HK - Hong Kong 415
SE - Svezia 411
RU - Federazione Russa 339
VN - Vietnam 267
DE - Germania 265
FR - Francia 245
FI - Finlandia 176
GB - Regno Unito 169
UA - Ucraina 148
BD - Bangladesh 119
IN - India 115
CA - Canada 93
AR - Argentina 75
ID - Indonesia 50
JP - Giappone 45
MX - Messico 45
IQ - Iraq 44
TR - Turchia 43
NL - Olanda 42
CI - Costa d'Avorio 40
ZA - Sudafrica 36
EC - Ecuador 33
ES - Italia 32
PH - Filippine 31
PL - Polonia 31
PK - Pakistan 29
CO - Colombia 25
VE - Venezuela 25
BE - Belgio 24
AT - Austria 21
SA - Arabia Saudita 21
UZ - Uzbekistan 20
IE - Irlanda 19
CR - Costa Rica 18
MA - Marocco 18
CL - Cile 17
TT - Trinidad e Tobago 17
CZ - Repubblica Ceca 15
MY - Malesia 15
LT - Lituania 14
NI - Nicaragua 14
SV - El Salvador 14
TN - Tunisia 14
CH - Svizzera 12
GT - Guatemala 12
IL - Israele 12
JM - Giamaica 12
PR - Porto Rico 12
TW - Taiwan 12
JO - Giordania 11
HN - Honduras 10
PY - Paraguay 10
CW - ???statistics.table.value.countryCode.CW??? 9
KE - Kenya 9
AE - Emirati Arabi Uniti 8
AZ - Azerbaigian 7
DZ - Algeria 7
PE - Perù 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
EG - Egitto 6
GP - Guadalupe 6
KR - Corea 6
DO - Repubblica Dominicana 5
ET - Etiopia 5
EU - Europa 5
SN - Senegal 5
AU - Australia 4
HR - Croazia 4
KZ - Kazakistan 4
RO - Romania 4
SC - Seychelles 4
UY - Uruguay 4
AL - Albania 3
AO - Angola 3
BB - Barbados 3
BO - Bolivia 3
EE - Estonia 3
IR - Iran 3
KG - Kirghizistan 3
MD - Moldavia 3
NP - Nepal 3
TH - Thailandia 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BG - Bulgaria 2
BZ - Belize 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
LB - Libano 2
MT - Malta 2
Totale 15.974
Salva come PNG Salva come JPEG
Città #
Ashburn 966
Singapore 740
San Jose 610
Chandler 595
Fairfield 444
Hong Kong 411
Woodbridge 373
Milan 367
Jacksonville 345
Nyköping 331
Houston 296
Beijing 263
Seattle 225
Bari 221
Ann Arbor 215
Cambridge 204
Council Bluffs 197
Wilmington 192
New York 160
Rome 150
Lauterbourg 109
Los Angeles 109
Lawrence 104
Roxbury 104
Dallas 98
Nanjing 91
Helsinki 86
Ho Chi Minh City 86
Santa Clara 84
São Paulo 76
Des Moines 71
Boardman 70
Munich 64
Hanoi 60
Brooklyn 55
Columbus 52
Princeton 50
Buffalo 47
Inglewood 45
Chicago 42
Abidjan 40
Moscow 38
Phoenix 38
Orem 34
Falkenstein 33
Marseille 32
Tokyo 32
London 29
Jakarta 28
Pune 27
Atlanta 26
Palermo 26
Rio de Janeiro 26
Shenyang 26
Figino 24
Frankfurt am Main 24
Paris 24
Florence 23
Toronto 23
Warsaw 23
Bologna 22
Brussels 22
Johannesburg 22
San Diego 22
Denver 21
Hebei 21
Montreal 21
Nanchang 21
Naples 21
Turin 21
Tashkent 20
Dearborn 19
Nuremberg 19
Stockholm 19
Baghdad 17
Poplar 17
Belo Horizonte 16
Chennai 16
Dong Ket 16
Tianjin 16
Washington 16
Brasília 15
Guangzhou 15
Mexico City 15
Noicattaro 14
Vienna 14
Managua 13
Manchester 13
Quito 13
Dhaka 12
Dublin 12
Jiaxing 12
Las Vegas 12
San José 12
Turku 12
Amsterdam 11
Ankara 11
Brno 11
Guayaquil 11
Porto Alegre 11
Totale 10.028
Salva come PNG Salva come JPEG
Nome #
L'immunoparesi nel mieloma multiplo 752
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 232
Autoimmune uveitis: clinical, pathogenetic, and therapeutic features 208
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 203
Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease 197
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 195
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 186
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 178
Autoantibodies to intracellular antigens: generation and pathogenetic role 177
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic 175
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study 175
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 175
Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center 174
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 174
Anti Th/To autoantibodies: a predictor markers for interstitial lung disease in undifferentiated connective tissue disease at risk of systemic sclerosis 170
Case series on amyloidosis and organ involvement: a single center experience 168
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma 165
Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus 165
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 165
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 163
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 162
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 162
Lupus vasculitis: An overview 159
Effectiveness and safety of belimumab in patients with active systemic lupus erythematosus: results from a large, nationwide, multicentric study. 157
Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature 155
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus. 155
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 153
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 152
Antiphospholipids syndrome complicated by a systemic capillary leak-like syndrome treated with steroids and intravenous immunoglobulins a case report 152
Rheumatic disorders as paraneoplastic syndromes 148
Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype 147
Vasculitides: Proposal for an integrated nomenclature 146
Cardiovascular risk in patients with Takayasu arteritis directly correlates with diastolic dysfunction and inflammatory cell infiltration in the vessel wall: a clinical, ex vivo and in vitro analysis. 142
CD20: A target antigen for immunotherapy of autoimmune diseases 142
Extra-articular manifestations of rheumatoid arthritis: an update 142
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 139
Beta-2 microglobulin-free HLA class I heavy chain (FHC) A3 and/or A30 soluble products contribute only minimally to serum FHC expression 139
Human CD4 internal antigen anti-idiotypic monoclonal antibody. Immunochemical and sequence analysis 138
Analisi molecolare di un anticorpo monoclonale (ACMO) anti-idiotipo 'immagine interna' dell'antigene CD4 138
Antibiotics or No Antibiotics, That Is the Question: An Update on Efficient and Effective Use of Antibiotics in Dental Practice 137
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 136
Adult-onset Still's disease with elderly onset: results from a multicentre study 135
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 129
Endothelial cells in tumor microenvironment: insights and perspectives 128
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 128
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 128
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 127
Clinical response and analysis of regulatory T cells (Tregs) in a cohort of patients with active Systemic Lupus Erythematosus (SLE) on treatment with belimumab. 127
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 126
Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study 124
Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma 123
Amicrobial pustulosis or erosive pustular dermatosis of the inguinal folds: broad of the same spectrum? 120
Anticorpi monoclonali nell'immunoterapia delle malattie autoimmuni 119
Mieloma multiplo e gammapatie monoclonali: quadri clinici, acquisizioni eziopatogenetiche e progressi terapeutici 117
Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes 115
B2 microglobulin-free heavy chain (FHC) of HLA class I antigen in patients with Hodgkin’s and non Hodgkin’s lymphomas 113
Echocardiographic alteration in patients with systemic lupus erythematosus affected by hepatic steatosis: a cross-sectional single center study 112
Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma 111
Beta2-m-free heavy chain levels of HLA-class I antigen combined with serum IgM or platelet count provide two reliable staging systems in multiple myeloma 110
HLA allele prevalence in disease-modifying antirheumatic drugs-responsive enthesitis and/or arthritis not fulfilling ASAS criteria: Comparison with psoriatic and undifferentiated spondyloarthritis 109
An 82-year-old woman with new onset of multiple purple-reddish nodules during treatment with abatacept for rheumatoid arthritis 109
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 108
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 107
Analisi molecolare di un anticorpo monoclonale (AcMo) anti-idiotipo “immagine interna” dell’antigene CD4 105
An atypical presentation of intestinal neuroendocrine tumor. 105
Epstein–Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions 104
Vasculiti primarie sistemiche 102
Raynaud’s phenomenon: from molecular pathogenesis to therapy 101
Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease 101
Constrictive pericarditis due to AL amyloidosis: a case report. 100
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 99
Beta-2 microglobulin-free HLA-A class I heavy chain (FHC) A3 and/or A30 soluble products contribute only minimally toserum FHC expression 97
B2 microglobulin (b2m)-free HLA class I heavy chain as prognostic marker of multiple myeloma 96
Membrane-type metalloprotease activity and HLA class I mRNA splicing in generating tFHC variants in multiple myeloma: clinical significance 95
Involvement of FAB subclass-specific determinants in the interaction of human IgG with Streptococcal Protein (PG) 94
The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma 93
Systemic lupus erythematosus therapy: new possibilities since 50 years 92
Ruolo degli autoanticorpi nelle patologie autoimmuni 90
Difficult therapeutic choices in a patient suffering from severe scleroderma and colon adenocarcinoma. 90
Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus 89
Monoclonal antibodies (mAb) in the immunotherapy (IT) of autoimmune disease (AD) 89
Clinical use of erythropoietin 89
Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis 89
Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity 88
P87 MEDIASTINAL SYNDROME REVEALED HEART LOCALIZATION OF A PRIMARY MEDIASTINAL B-CELL LYMPHOMA 87
La neutropenia nei pazienti in trattamento: differenziazione dei fattori di crescita 87
Ruolo degli autoanticorpi nelle patologie autoimmuni 85
Paradoxical embolism: relationship between foramen ovale pervious and renal infarction. 84
Minimum structural requirement for CD4 mimicry by anti-idiotipic mAb 16D7 83
Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study 82
Vasculiti primarie sistemiche 81
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus 81
Tumor necrosis factor‑α in systemic lupus erythematosus: Structure, function and therapeutic implications (Review) 81
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche 80
Beta 2-microglobulin-free heavy chain (FHC) of HLA class I antigen in patients with Hodgkin's and non-Hodgkin's lymphomas 80
BETA-2 microglobulin (beta2m)-free HLA Class I heavy chain as prognostic marker of multiple myeloma 80
Dosaggio della catena pesante degli antigeni di Istocompatibilita' in pazienti con mieloma multiplo (MM) 79
Immunoparesisi in multiple myeloma 79
Two structurally different peptides mimic a CD20 epitope recognized by rituximab 79
null 78
Totale 13.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022650 0 0 0 0 28 65 60 45 38 43 143 228
2022/20231.530 193 201 114 140 164 216 33 180 217 11 42 19
2023/2024701 49 107 37 65 51 179 12 48 23 29 25 76
2024/20252.429 90 26 192 71 62 195 265 241 83 151 359 694
2025/20265.582 781 253 347 634 622 304 625 202 572 480 183 579
2026/20271.758 213 271 413 832 29 0 0 0 0 0 0 0
Totale 16.454